Antoni Gofron, MD
Endocrinology, Diabetes & Metabolism · Milwaukee, WINPI 1871501593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 130 payments — averaging $36.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$950
- Sanofi-aventis U.S. LLC$557
- Medtronic$506
- Dexcom, Inc.$432
- Amgen$399
- Lilly USA, LLC$340
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,69899%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $950 |
| Sanofi-aventis U.S. LLC | 13 | $557 |
| Medtronic(2 entities) | 16 | $506 |
| Dexcom, Inc. | 7 | $432 |
| Amgen | 10 | $399 |
| Lilly USA, LLC | 7 | $340 |
| Abbott | 10 | $263 |
| IBSA Pharma Inc. | 5 | $240 |
| Tandem Diabetes Care, Inc. | 1 | $159 |
| Amarin Pharma, Inc. | 1 | $125 |
| Sequel Med Tech, LLC | 2 | $118 |
| Nestle Healthcare Nutrition Inc. | 1 | $115 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Insulet Corporation | 2 | $54 |
| Recordati_rare_diseases_inc. | 3 | $51 |
| Boehringer Ingelheim | 2 | $48 |
| Radius Health, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $38 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| AstraZeneca | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Tolmar, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$360
- SOLIQUA 100/33$277
- Ozempic$217
- Tirosint$172
- t:slim X2 Insulin Pump with Control-IQ$159
- FreeStyle Libre 2$155
- MINIMED 780G$133
- TEPEZZA$128
- EVENITY$125
- ZEPBOUND$125
- Vascepa$125
- Tresiba$124
- Victoza$124
- Xultophy 100/3.6$124
- MOUNJARO$117
- ZENPEP$115
How this compares
$4,731 in reported general payments places this provider in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 533 | $607,147 |
| TrulicityDulaglutide | 210 | $277,268 |
| MounjaroTirzepatide | 80 | $95,674 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $66,776 |
| TradjentaLinagliptin | 86 | $62,507 |
| JardianceEmpagliflozin | 44 | $41,941 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 281 | $38,362 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 105 | $29,723 |
| Humalog Kwikpen U-100Insulin Lispro | 113 | $29,220 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $23,547 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 71 | $22,476 |
| Repatha SureclickEvolocumab | 28 | $20,466 |
| Novolog FlexpenInsulin Aspart | 67 | $16,227 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 150 | $12,811 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $12,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $950 | $619,324564 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $340 | $375,273306 claims |
| Boehringer IngelheimTradjenta, Jardiance | $48 | $104,448130 claims |
| AstraZenecaByetta, Farxiga | $31 | $15,78724 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $557 | $13,91334 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $58 | $3,714309 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Milwaukee
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Adriana IoachimescuMilwaukee$26K
- Catherine ZhangMilwaukee$16K
- Timur GusovMilwaukee$5K
- Anil ChandelMilwaukee$3K
- Michael VossMilwaukee$2K
- Olena KlindukhovaMilwaukee$1K
- Usonwanne IbekweMilwaukee$1K
- Veitla RaoMilwaukee$658
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.